DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
03/06/2019 - 7:00 pm
Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB)
03/05/2019 - 10:10 pm
DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational UpdateDownload PDF (160 KB)
03/05/2019 - 7:30 am
DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of DirectorsDownload PDF (144 KB)